Smith EP, Witherspoon DP, Bhargava S, Bermudez JM. Cultural values and behavior among African American and European American children. J Child Fam Stud. 2019 May 1;28:1236-49.
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
DiBenedetti DB, Brown TM, Danchenko N. Assessing patient and caregiver experiences with symptoms and behaviors associated with schizophrenia. J Depress Anxiety. 2016 Jul 17;5(3):240. doi: 10.4200/2167-1044.1000240
Brown TM, DiBenedetti DB, Danchenko N, Weiller E, Fava M. Symptoms of anxiety and irritability in patients with major depressive disorder. J Depress Anxiety. 2016 Jun 18;5:237. doi: 10.4200/2167-1044.1000237
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Navarro P, Ascaso C, Garcia-Esteve L, Aguado J, Torres A, Martín-Santos R. Postnatal psychiatric morbidity: a validation study of the GHQ-12 and the EPDS as screening tools. General Hospital Psychiatry. 2007 Jan;29(1):1-7.